SOX9: Can this protein enable a molecular reversal that could lead to colorectal cancer? Nilay Sethi, MD - Synopsis below extracted from the video transcript.
Trimodality: In addition to Trastuzumab for HER2+ Esophageal Adenocarcinoma: NRG Oncology RTOG 1010 Phase III Trial Lisa Kachnic MD - Synopsis below extracted from the video transcript.
Gastrointestinal Malignancies Research Advancements: Insights from Farshid Dayyani, MD - Synopsis below extracted from the video transcript.